vs
Side-by-side financial comparison of LZ Technology Holdings Ltd (LZMH) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $57.8M, roughly 1.2× LZ Technology Holdings Ltd). LZ Technology Holdings Ltd runs the higher net margin — -10.5% vs -49.0%, a 38.6% gap on every dollar of revenue. LZ Technology Holdings Ltd produced more free cash flow last quarter ($-6.8M vs $-84.7M).
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
LZMH vs VRDN — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.8M | $70.6M |
| Net Profit | $-6.0M | $-34.6M |
| Gross Margin | 3.0% | — |
| Operating Margin | -10.1% | -56.7% |
| Net Margin | -10.5% | -49.0% |
| Revenue YoY | — | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.2M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.5M | $503.0M |
| Total Assets | $71.5M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $490.9M | ||
| Q2 25 | $2.2M | — |
| Q3 25 | — | $503.0M | ||
| Q2 25 | $9.5M | — |
| Q3 25 | — | $577.1M | ||
| Q2 25 | $71.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.7M | $-84.6M |
| Free Cash FlowOCF − Capex | $-6.8M | $-84.7M |
| FCF MarginFCF / Revenue | -11.7% | -120.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-84.6M | ||
| Q2 25 | $-6.7M | — |
| Q3 25 | — | $-84.7M | ||
| Q2 25 | $-6.8M | — |
| Q3 25 | — | -120.1% | ||
| Q2 25 | -11.7% | — |
| Q3 25 | — | 0.2% | ||
| Q2 25 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
